EMA recommends Pfizer's jab adapted for new virus strains

Monday, 12. September 2022 18:01

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) confirmed on Monday its recommendation of Pfizer Inc. and BioNTech SE's vaccine against COVID-19 adapted to target specifically the Omicron strains BA.4 and BA.5 as well as the original one.

Following its review, the CHMP concluded the new version of the jab is more successful in providing protection against BA.4 and BA.5 variants than the one made initially, Comirnaty. It recommended the use of the treatment in people aged 12 and more "who have received at least a primary course of vaccination against COVID-19."

The EMA recently recommended the use of Pfizer and BioNTech's booster shot modified to target the Omicron strain BA.1.

Related Links: BioNTech SEPfizer Inc.
Baha Breaking News (BBN) / JR